Workshop on Immune System Engineering for Targeted Tolerance in Type 1 Diabetes (T1D)

Event Details

Background

Type 1 diabetes results in part from the autoimmune destruction of the insulin-producing pancreatic beta cells. It may be possible to change the course of the disease by interfering with autoimmune pathogenesis and re-establishing tolerance. For example, immune responses may be de-activated specifically and safely through the development of tolerizing vaccines, or through the direct manipulation of regulatory and other cells for applications in cell therapy.

In this Workshop, scientists from diverse fields (bioengineering, microbiomics, cancer immunology, etc.) will come together with diabetes experts to discuss how new knowledge, tools and technologies may be applied to reverse autoimmunity.

Meeting Objectives

Examples of topics for discussion include:

1. Development of safe tolerizing adjuvants or delivery systems
   1. The development of materials that deliver specific antigens in ways that direct the immune response towards active tolerance.
   2. Understanding of anti-inflammatory or autoimmune mechanisms that are specific and can be manipulated or targeted.
2. Engineer immune system cells for use as highly specific therapeutics
   1. Re-directing effector immune cells to eliminate pathogenic cell types.
   2. Re-directing or strengthening immune regulatory cells to dampen the overactive immune system at sites of autoimmune damage.

Registration Deadline

October 15, 2017

This meeting is being held in conjunction with the Autoantigens Discovery and Characterization in Type 1 Diabetes workshop.

Agenda

November 1, 2017

5:30 p.m. – 5:35 p.m.

Call to Order and Introduction
Lisa Spain, NIDDK, Bethesda

5:35 p.m. – 6:30 p.m.

Keynote Opening Lecture
Jerry Nepom, Benaroya at VMU, Seattle

6:30 p.m. – 8:00 p.m.

Dinner (TBD)

November 2, 2017

8:30 a.m. – 8:35 a.m.

Call to order
Lisa Spain

Session I: Lessons Learned in Promoting Tolerance in Type 1 Diabetes

8:35 a.m. – 8:45 a.m.

Introduction
Qizhi Tang, University of California, San Francisco

8:45 a.m. – 9:10 a.m.

Clinical Trials With Proinsulin Peptide For Tolerization
Mark Peakman, King’s College, London

9:10 a.m. – 9:30 a.m.

Type 1 Diabetes TrialNet: Past, Present, Future
Carla Greenbaum, Benaroya, Seattle

9:30 a.m. – 10:00 a.m.

Features of Human T1D—nPOD findings Thus Far
Todd Brusko (PDF, 136.79 KB) , University of Florida, Gainesville

10:00 a.m. – 10:15 a.m.

Break

10:15 a.m. – 10:45 a.m.

Gut Microbiome and Tolerance
Daniel Graham (PDF, 117.91 KB) , Broad Institute, Cambridge

10:45 a.m. – 11:15 a.m.

Microbial Metabolites
CR Mackay, Monash University, Melbourne

11:15 a.m. – 11:45 a.m.

Panel Discussion: Opportunities, Gaps, Challenges
Moderators: Bart Roep & Eddie James

11:45 a.m. – 12:30 p.m.

Lunch (on your own)

Session II: Manipulating the Immune System for Tolerance: Adjuvants and Cellular Engineering

12:30 p.m. – 1:00 p.m.

Introduction
Nik Petrovsky, Flinders University, Flinders

1:00 p.m. – 1:30 p.m.

Celiac Peptides
Bob Anderson, ImmusanT, Boston

1:30 p.m. – 2:00 p.m.

Biomaterials for Immunological Tolerance Technology for Preventing Immunity
Jeff Hubbell, University of Chicago, Chicago

2:00 p.m. – 2:30 p.m.

Therapies to Promote Tregs
Allison Bayer (PDF, 137.58 KB) , U Miami, Miami

2:30 p.m. – 2:45 p.m.

Break

2:45 p.m. – 3:15 p.m.

CAR-T Cancer Immunotherapy and Beyond
Michel Sadelain, Memorial Sloan-Kettering, New York

3:15 p.m. – 3:45 p.m.

Cell Therapy With Genetically Engineered Regulatory T Cells to Induce Immunological Tolerance
Maria-Grazia Roncarolo, Stanford University, Palo Alto

3:45 p.m. – 4:15 p.m.

CAR-Treg Immunotherapy
David Scott, Uniformed Services University, Bethesda

4:15 p.m. – 4:30 p.m.

Break

4:30 p.m. – 5:00 p.m.

Outlook for Promoting Antigen Specific Tolerance
Matthias von Herrath (PDF, 88.35 KB) , Novo Nordisk/LIAI, Seattle/La Jolla

5:00 p.m. – 5:30 p.m.

Discussion Panel: Opportunities, Gaps, Challenges
Moderators: Alice Tomei (PDF, 274.44 KB) & Aaron Michels

5:30 p.m.

Concluding Remarks and Overall Discussion